»¶ÀÖ¶·µØÖ÷_Õ©½ð»¨ÓÎÏ·

ZHANG Lintao ^¢Ù

(The First People¡äs Hospital of Zhoukou, Zhoukou 466700, China)

Abstract Objective: To investigate the clinical efficacy of nicorandil combined with Xuezhikang in the treatment of patients with coronary heart disease angina pectoris (CHD-AP). Methods: A total of 78 patients with CHD-AP were selected and divided into the nicorandil group, Xuezhikang group and combined treatment group by random number table method group, with 26 cases in each group. All patients in the three groups received three months treatment. The clinical efficacy, blood lipid index, myocardial enzyme, vascular endothelial function and adverse reaction were compared between the three groups. Results: The total effective rate of 92.31 % in the combined group was significantly higher than that of 65. 38 % in the nicorandil group and 61.54 % in the Xuezhikang group with a statistically significant difference (P<0.05);after treatment, LDL-C, TC and TG in the combined treatment group were lower than those in the nicorandil and Xuezhikang group, while HDL-C was higher than that in the nicorandil and Xuezhikang groups (P<0.05); cTnI, CK, CK-MB, LDH, vWF, ET-1, and MCP-1 in the combined treatment group were lower than those in the nicorandil group and the Xuezhikang group, and NO was higher than that in the nicorandil group and the Xuezhikang group (P<0.05); there was no significant difference in the incidence of adverse reactions among the three groups (P>0.05). Conclusion: Nicorandil combined with Xuezhikang was effective in treating patients with CHD-AP, which can improve the myocardial function and vascular endothelial cell functions as well.

Keywords: nicorandil; Xuezhikang; coronary heart disease angina pectoris; myocardial function

DOI:10.19296/ j.cnki.1008-2409.2023-01-018

PDF download:click to download